Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP) Recommended Immunization Schedule (2018-19) and Update on Immunization for Children Aged 0 Through 18 Years
- 28 Downloads
There is a need to revise/review recommendations regarding existing vaccines in view of current developments in vaccinology.
Advisory Committee on Vaccines and Immunization Practices (ACVIP) of Indian Academy of Pediatrics (IAP) reviewed the new evidence, had two meetings, and representatives of few vaccine manufacturers also presented their data. The recommendations were finalized unanimously.
To revise and review the IAP recommendations for 2018–19 and issue recommendations on existing and certain new vaccines.
The major changes in the IAP 2018–19 Immunization Timetable include administration of hepatitis B vaccine within 24 hours of age, acceptance of four doses of hepatitis B vaccine if a combination pentavalent or hexavalent vaccine is used, administration of DTwP or DTaP in the primary series, and complete replacement of oral polio vaccine (OPV) by injectable polio vaccine (IPV) as early as possible. In case IPV is not available or feasible, the child should be offered three doses of bivalent OPV. In such cases, the child should be advised to receive two fractional doses of IPV at a Government facility at 6 and 14 weeks or at least one dose of intramuscular IPV, either standalone or as a combination, at 14 weeks. The first dose of monovalent Rotavirus vaccine (RV1) can be administered at 6 weeks and the second at 10 weeks of age in a two-dose schedule. Any of the available rotavirus vaccine may be administered. Inactivated influenza vaccine (either trivalent or quadrivalent) is recommended annually to all children between 6 months to 5 years of age. Measles-containing vaccine (MMR/MR) should be administered after 9 months of age. Additional dose of MR vaccine may be administered during MR campaign for children 9 months to 15 years, irrespective of previous vaccination status. Single dose of Typhoid conjugate vaccine (TCV) is recommended from the age of 6 months and beyond, and can be administered with MMR vaccine if administered at 9 months. Four-dose schedule of anti-rabies vaccine for Post Exposure Prophylaxis as recommended by World Health Organization in 2018, is endorsed, and monoclonal rabies antibody can be administered as an alternative to Rabies immunoglobulin for post-exposure prophylaxis.
KeywordsGuidelines Immunity Infections Prevention Vaccination
Unable to display preview. Download preview PDF.
- 2.Hepatitis B vaccines: WHO position paper–No 27, 2017, World Health Organization. Weekly epidemiological record. No 27, 2017, 92, 369–392.Google Scholar
- 3.Elizabeth D. Barnett, Give first dose of HepB vaccine within 24 hours of birth: American Academy of Pediatrics August 28, 2017. Available from: http://www.aappublications.org/news/2017/08/28/HepB082817. Accessed Nov 6, 2018.Google Scholar
- 4.Cherry JD. Pertussis and Immunizations: Facts, Myths, and Misconceptions. Available from: http://aap–ca.org/pertussis–and–immunizations–facts–myths–andmisconceptions. Accessed November 6, 2018.Google Scholar
- 6.Jackson DW, Rohani P. Perplexities of pertussis: Recent global epidemiological trends and their potential causes. Epidemiol Infect. 2013;16:1–13.Google Scholar
- 8.Centers for Disease Control and Prevention (CDC). Pertussis epidemic—Washington, 2012. Morb Mortal Wkly Rep. 2012;61:517–22.Google Scholar
- 9.Pertussis vaccines: WHO Position Paper–August 2015 No. 35. World Health Organization. Weekly Epidemiological Record. 2015;90:433–60.Google Scholar
- 10.World Health Organization. Pertussis Vaccine Evidence to Recommendations (WHO). Available from: http://www.who.int/immunization/position_papers/Pertussis GradeTable3.pdf. Accessed November 6, 2018.Google Scholar
- 11.WHO Position paper on Pertusis Vaccine, 2005. World Health Organization. Weekly Epidemiological Record. 2005;4:29–40.Google Scholar
- 15.Okada K, Ohashi Y, Matsuo F, Uno S, Soh M, Nishima S. Effectiveness of an acellular pertussis vaccine in Japanese children during a non–epidemic period: a matched casecontrol study. Epidem Infection. 2009:137:124–30.Google Scholar
- 16.World Health Organization. WHO SAGE Pertussis Working Group. Background Paper. SAGE April 2014. Available from: http://www.who.int/immunization/sage/meetings/2014/april/1_Pertussis_background_FINAL4_web.pdf? ua=. Accessed November 15, 2018.Google Scholar
- 17.World Health Organization. Use of Fractional Dose IPV in Routine Immunization Programmes: Considerations for Decision–making. Available from: http://www.who. int/immunization/diseases/poliomyelitis/endgame_objective2/inactivated_polio_vaccine/fIPV_considerations_for_decision–making_April2017.pdf?ua=1. Accessed November 6, 2018.Google Scholar
- 18.Vasishtha VM, Choudhary J, Yadav S, Unni JC, Jog P, Kamath SS, et al. Introduction of inactivated poliovirus vaccine in National Immunization Program and polio endgame strategy. Indian Pediatr. 2016;53(Suppl.1):S65–9.Google Scholar
- 19.Bahl S, Verma H, Bhatnagar P, Haldar P, Satapathy A, Arun Kumar KN, et al. Fractional–dose inactivated poliovirus vaccine immunization campaign — Telangana State, India, June 2016. MMWR. 2016;65:859–63.Google Scholar
- 21.Clarke E, Saidu Y, Adetifa JU, Adigweme I, Hydara MB, Bashorun AO, et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measlesrubella combined vaccine and yellow fever vaccine and when given via different administration routes: A phase 4, randomised, non–inferiority trial in The Gambia. Lancet Glob Health. 2016;4:e534–47.CrossRefGoogle Scholar
- 24.Polio vaccines: WHO Position Paper, March 2016. World Health Organization. Weekly Epidemiological Record. 2016;91:145–68.Google Scholar
- 25.World Health Organization. Detailed Review Paper on Rotavirus Vaccines (presented to the WHO Strategic Advisory Group of Experts (SAGE) on Immunization in April 2009). Geneva, World Health Organization, 2009. Available from: http://www.who.int/immunization/sage/3_Detailed_Review_Paper_on_Rota_Vaccines_17_3_2009.pdf. Accessed November 08, 2018.Google Scholar
- 27.Rotavirus vaccines WHO Position Paper–January 2013. Weekly Epidemiological Record. 2013;88:49–64.Google Scholar
- 28.Rotavirus. In: Hamborsky J, Kroger A, Wolfe S, eds. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine–preventable Diseases. 13th ed. Washington DC: Public Health Foundation, 2015. Available from:https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/rota.pdf. Accessed November 15, 2018.Google Scholar
- 29.World Health Organization. Rotavirus Report, February 2012. Rotavirus Vaccines Schedules: A Systematic Review of Safety and Efficacy from Randomized Controlled Trials and Observational Studies of Childhood Schedules Using RV1 and RV5 Vaccines. Available from: http://www.who.int/immunization/sage/meetings/2012/april/Soares_K_et_al_SAGE_April_rotavirus.pdf. Accessed November 08, 2018.Google Scholar
- 30.World Health Organization. Grading of Scientific Evidence–Tables 1–4: Does RV1and RV5 induce protection against rotavirus morbidity and mortality in young children both in low and high mortality settings? Available from: http://www.who.int/immunization/position_papers/rotavirus_grad_rv1_rv5_protection. Accessed November 8, 2018.Google Scholar
- 32.World Health Organization. Background Paper on Typhoid Vaccines for SAGE Meeting (October 2017). Available from: http://www.who.int/immunization/sage /meetings/2017/october/1_Typhoid_SAGE_background_paper_Final_v3B.pdf. Accessed November 08, 2018.Google Scholar
- 33.World Health Organization. Guidelines on The Quality, Safety and Efficacy of Typhoid Conjugate Vaccines, 2013. Available from: http://www.who.int/biologicals/areas/vaccines/TYPHOID_BS2215_doc_v1.14_WEB_VERSION. pdf. Accessed July 12, 2016.Google Scholar
- 35.World Health Organization. Background Paper to SAGE on Typhoid Policy Recommendations. 2017. Available from: http://www.who.int/immunization/sage/meetings/2017/october/1_Typhoid_SAGE_background_paper_Final_v3B. pdf?ua=1. Accessed November 08, 2018.Google Scholar
- 36.Typhoid vaccines: WHO Position Paper–March 2018. Weekly Epidemiological Record. 2018;93:153–72.Google Scholar
- 38.Vashishtha VM, Yewale VN, Bansal CP, Mehta PJ. Indian Academy of Pediatrics, Advisory Committee on Vaccines and Immunization Practices (ACVIP). IAP perspectives on measles and rubella elimination strategies. Indian Pediatr. 2014;51:719–22.Google Scholar
- 39.Centers for Disease Control and Prevention. Measles, Mumps, and Rubella (MMR) Vaccination: What Everyone Should Know. Available from: https://www.cdc.gov/vaccines/vpd/mmr/public/index.html. Accessed November 18, 2018.Google Scholar
- 41.Rudan I, Theodoratou E, Zgaga L, Nair H, Chan KY, Tomlinson M, et al. Setting priorities for development of emerging interventions against childhood pneumonia, meningitis and influenza. J Glob Health. 2012;2:10304.Google Scholar
- 42.Venkatesh M, Doarn CR, Steinhoff M, Yung J. Assessment of burden of seasonal influenza in India and consideration of vaccination policy. Glob J Med Pub Health. 2016;5:1–10. Available from: http://www.gjmedph.com/uploads/R1–Vo5No5.pdf. Accessed November 18, 2018.Google Scholar
- 44.Hirve S, Krishnan A, Dawood FS, Lele P, Saha S, Rai S, et al. Incidence of influenza–associated hospitalization in rural communities in western and northern India, 2010–2012: A multi–site population–based study. J Infect. 2015;70: 160–70.Google Scholar
- 49.Gogtay NJ, Munshi R, Ashwath Narayana DH, Mahendra BJ, Kshirsagar V, Gunale B, et al. Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: A phase 2/3, randomized, single–blind, noninferiority, controlled study. Clin Infect Dis. 2018;66:387–95.CrossRefGoogle Scholar